“Polypharmacy,” or the concurrent use of multiple medications, can lead to harmful drug interactions—which is especially dangerous for cancer patients about to undergo therapy, according to a study led by Wilmot Cancer Institute researchers.
“Patient stories, as you know, can either make or break a story,” said Laurie McGinley, a former health and science editor at The Washington Post who is now on the board of Patient Action for Cancer Research, or PACR, a new advocacy organization aimed at organizing and amplifying patient voices in an effort to protect life-saving federal health research.
